### Supplementary Table 1. Quality of Included Studies as Assessed by the Newcastle-Ottawa Scale

| Study               | Selection | Comparability | Outcome | Total Score (out of 9) |
|---------------------|-----------|---------------|---------|------------------------|
| **mPC Studies**     |           |               |         |                        |
| Beyer 2016*         | ****      | *             | ***     | 8                      |
| Park 2016*          | ***       | **            | *       | 6                      |
| Patel 2016*         | ****      | **            | **      | 8                      |
| Schmidt 2016*       | ****      | **            | **      | 8                      |
| Abrams 2017*        | ****      | **            | ***     | 9                      |
| Braiteh 2017*       | ****      | **            | ***     | 9                      |
| Caponnetto 2017**   | ***       | *             | **      | 6                      |
| Kim 2017**          | ****      | **            | ***     | 9                      |
| Mañes-Sevilla 2017* | ****      | *             | ***     | 8                      |
| McBride 2017*       | ****      | *             | **      | 7                      |
| Watanabe 2017*      | ***       | *             | *       | 5                      |
| Barrera 2018*       | ****      | *             | ***     | 8                      |
| Cartwright 2018*    | ****      | *             | ***     | 8                      |
| Cho 2018*           | ****      | **            | **      | 8                      |
| Kang 2018*          | ****      | *             | ***     | 8                      |
| Kim 2018*           | ****      | **            | ***     | 9                      |
| Pacheco-Barcia 2018 |           |               |         |                        |
| Vivaldi 2018*       |           |               |         |                        |
| Barrera 2019*       | ***       | **            | *       | 6                      |
| Henkel 2019*        | ***       | **            | *       | 6                      |
| Javed 2019*         | ****      | *             | ***     | 8                      |
| **aPC Studies**     |           |               |         |                        |
| Cherniawsky 2017*   | ***       | **            | *       | 6                      |
| Kasi 2017*          | ***       | *             | *       | 5                      |
| Maeda 2017*         | ***       | *             | **      | 6                      |
| Muranaka 2017*      | ****      | *             | **      | 7                      |
| Papneja 2017*       | ****      | **            | ***     | 9                      |
| Shahda 2017*        | ****      | **            | *       | 7                      |
| Wang 2017*          | ****      | *             | ***     | 8                      |
| Franco 2018*        | ****      | *             | ***     | 8                      |
| Helen 2018*         | ****      | **            | ***     | 9                      |
| Kudlovič 2018*      | ****      | **            | **      | 8                      |
| Tahara 2018*        | ***       | *             | **      | 6                      |
|                          | **** | *   | *** | 8   |
|--------------------------|------|-----|-----|-----|
| Hegewisch-Becker 2019^b  | **** | *   | *** | 8   |
| Mean NOS score           | 7.47 |

aPC, advanced pancreatic cancer; mPC, metastatic pancreatic cancer; NOS, Newcastle-Ottawa Scale.

^a The Newcastle-Ottawa Scale assigns a maximum of 4, 2, and 3 stars for selection, comparability, and outcome parameters, respectively.

^b A total score of 9 denotes the highest quality.
